In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now.

Dr. Warris Bokhari, the CEO and co-founder of Claimable, discussed utilizing AI to fight health insurance denials and other subjects on CNBC’s “Squawk Box” on July 21.

The majority of Americans have experienced the annoyance of having their health insurance rejected, frequently without any recourse after contacting carriers by email and phone. Dr. Bokhari’s technology, which uses artificial intelligence (AI) to challenge care denials for around 70 autoimmune diseases, including Crohn’s disease, has the potential to change this.

After a patient fills out a form, AI handles the next steps, searching for relevant federal and state laws and insurance plans.

Dr. Bokhari claims that the platform was developed following 10 years of monitoring a unique problem facing America: 850 million denials take place each year, and only about 1% of them are ever appealed. These numbers indicate that between 70 and 90 million Americans deal with insurance-related issues annually, such as denials.

The service, which was first introduced in the US on October 2, 2024, helps people appeal care denials for 70 autoimmune conditions by using AI to generate appeal letters based on healthcare plans.

With these trends in mind, let’s look at the hot healthcare stocks to buy right now.

Our Methodology 

For our methodology, we first used a screener to filter stocks with a market capitalization exceeding $2 billion and a six-month total return greater than 20%. From this filtered list, we selected the top seven stocks and ranked them in ascending order based on their total returns.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 7 hot healthcare stocks to buy right now.

7. Qiagen N.V. (NYSE:QGEN)

6 Months Total Return: 20.31% 

Qiagen N.V. (NYSE:QGEN), a global leader in molecular diagnostics and sample preparation technologies, continues to advance its position in clinical laboratories, biopharmaceuticals, and life science research. Headquartered in the Netherlands and operating in over 30 countries under CEO Thierry Bernard, the company provides a wide range of solutions, including nucleic acid extraction systems, PCR reagents, digital PCR platforms, next-generation sequencing kits, and proteomics tools. The company stands seventh on our list among the hot stocks to buy.

In Q2 2025, Qiagen N.V. (NYSE:QGEN) reported net sales of $534 million, marking a 7% increase from the prior year, with an adjusted operating income margin of 29.9%, up 1.5 percentage points. Growth was fueled by strong demand for products such as QIAstat-Dx, which grew 41% CER, and QuantiFERON, which increased 11% CER. Reflecting confidence in its operational momentum, the business raised its full-year 2025 net sales growth outlook to 4–5% CER and reaffirmed its adjusted diluted EPS targets.

Innovation remains central to Qiagen N.V. (NYSE:QGEN)’s strategy. The recent launch of QIAseq xHYB Long Read Panels enhances target enrichment for long-read sequencing platforms, enabling more detailed analysis of complex genomic regions, structural variants, HLA typing, and repeat expansions. Additionally, QGEN continues to expand its digital and automation offerings, with growth in QIAcuity digital PCR systems and the QIAGEN Digital Insights software platform, while preparing to launch three new instruments by late 2025 to strengthen its molecular diagnostics capabilities.

6. Humana Inc. (NYSE:HUM)

6 Months Total Return: 20.33% 

Humana Inc. (NYSE:HUM), a leading U.S. health insurer, specializes in Medicare Advantage plans, government-sponsored programs, and integrated healthcare services through its insurance and CenterWell health services segments. The company serves millions of Medicare Advantage members and emphasizes value-based care models and coordinated healthcare delivery.

In 2025, Humana Inc. (NYSE:HUM) raised its revenue guidance to at least $128 billion, driven by stronger-than-expected medical cost control and growth in its pharmacy business. This increase reflects the business’s operational resilience amid ongoing challenges in the healthcare insurance sector. A key factor has been the strategic refinement of Medicare Advantage offerings, including plan adjustments in higher-cost counties that reduced the medical loss ratio while retaining more individual members than anticipated.

Humana Inc. (NYSE:HUM)’s CenterWell health services division, encompassing primary care, pharmacy, and home health services, also contributed to growth. Notably, CenterWell Pharmacy’s partnership with Novo Nordisk to sell GLP-1 medications directly to consumers strengthened revenue and diversified HUM’s healthcare delivery capabilities. These initiatives demonstrate the firm’s commitment to expanding beyond traditional insurance into comprehensive healthcare solutions.